erlotinib hydrochloride has been researched along with Meningeal Neoplasms in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, J; Jiang, C; Li, H; Lin, Y; Qian, X; Xie, Y; Yin, Z; Yu, T; Zheng, S | 1 |
| Ke, L; Li, S; Meng, X; Wu, H; Yu, J; Zhang, H; Zhang, X; Zhou, H | 1 |
| Akerley, W; Chalmers, A; Jensen, L | 1 |
| Jing, W; Kong, L; Wang, H; Yu, J; Zhu, H | 1 |
| Guan, S; Ji, G; Yao, X; Zhang, C | 1 |
| Heideman, DA; Kuiper, JL; Postmus, PE; Smit, EF; Thunnissen, E; van Wijk, AW | 1 |
| Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
| Iwakami, S; Katsura, Y; Kido, K; Ko, R; Namba, Y; Sasaki, S; Shukuya, T; Takahashi, K; Tominaga, S; Yoshioka, Y | 1 |
| Ichikado, K; Kawamura, K; Sakata, Y; Shingu, N | 1 |
| Jo, H; Kanemaru, R; Kasuga, F; Koyama, R; Morio, Y; Nagaoka, T; Shiota, S; Takahashi, K; Takekawa, H | 1 |
| Balleyguier, C; Besse, B; Soria, JC; Wagner, M | 1 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, CS; Kim, DW; Kim, HJ; Kim, TY; Kim, YJ; Lee, SH; Oh, DY; Yi, HG | 1 |
| Dhruva, N; Socinski, MA | 1 |
| Abrey, LE; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Norden, AD; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Clarke, JL; Lassman, AB; Miller, VA; Pao, W; Wu, N | 1 |
| Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Kuhara, H; Minami, T; Nagatomo, I; Osa, A; Tachibana, I; Takahashi, R; Takeda, Y; Tetsumoto, S | 1 |
| Fujiwara, K; Hamada, N; Horita, N; Hotta, K; Kamei, H; Kiura, K; Segawa, Y; Takata, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Umemura, S; Yamane, H; Yoshioka, H | 1 |
| Hamatani, Y; Kim, YH; Masago, K; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Dong, XR; Huang, J; Liu, L; Lu, HD | 1 |
| Nagpal, S; Riess, J; Wakelee, H | 1 |
| Choong, NW; Davies, GC; Dietrich, S; Husain, AN; Lipkowitz, S; Ma, PC; Nallasura, V; Salgia, R; Seiwert, TY; Tretiakova, MS | 1 |
3 review(s) available for erlotinib hydrochloride and Meningeal Neoplasms
| Article | Year |
|---|---|
Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Male; Meningeal Neoplasms; Mutation; Patents as Topic; Progression-Free Survival; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinolines | 2021 |
Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Meningeal Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome | 2018 |
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
3 trial(s) available for erlotinib hydrochloride and Meningeal Neoplasms
| Article | Year |
|---|---|
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Tomography, X-Ray Computed | 2010 |
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2010 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
18 other study(ies) available for erlotinib hydrochloride and Meningeal Neoplasms
| Article | Year |
|---|---|
Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Fusion; High-Throughput Nucleotide Sequencing; Humans; Injections, Spinal; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Metastasis; Pemetrexed; Septins | 2022 |
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
Topics: Acrylamides; Aged; Aniline Compounds; Brain; Carcinoma, Non-Small-Cell Lung; Cerebrospinal Fluid; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors | 2017 |
Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Multimodal Imaging; Mutation; Treatment Outcome | 2018 |
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2016 |
Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Mutation; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2016 |
Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Mutation | 2016 |
Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Topics: Adenocarcinoma; Cerebrospinal Fluid; Diagnosis, Differential; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2008 |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.
Topics: Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Quinazolines | 2012 |
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
A case report: successful treatment of meningeal metastasis with concurrent whole brain radiotherapy and erlotinib in a patient with non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Treatment of leptomeningeal spread of NSCLC: a continuing challenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytarabine; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Meningeal Neoplasms; Methotrexate; Mutation; Pemetrexed; Quinazolines; Radiation Dosage | 2012 |
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Meningeal Neoplasms; Mutation; Quinazolines; Ribs; Treatment Failure | 2006 |